Weed (BUDZ) Net Income towards Common Stockholders (2010 - 2026)

Weed's (BUDZ) quarterly Net Income towards Common Stockholders came in at -$175256.0 in Q1 2026, up 60.21% year-on-year from -$109391.3 in Q1 2025, and up 91.74% quarter-over-quarter from -$2.1 million in Q4 2025.

Weed (BUDZ) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Weed's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$175256.0 for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 60.21% year-over-year to -$175256.0 in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 217.63% decrease from a year earlier, with the FY2025 full-year figure at -$2.7 million, down 437.35% from the prior year.
  • Net Income towards Common Stockholders grew to -$175256.0 in Q1 2026 per BUDZ's latest filing, from -$2.1 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $734248.0 in Q3 2023 and bottomed at -$4.0 million in Q2 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$192312.0 (2022), against an average of -$989428.2.
  • Across the five-year window, Net Income towards Common Stockholders sank 1543.81% in 2022 and soared 124.53% in 2023, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$192312.0 in 2022, then slumped by 105.07% to -$394368.0 in 2023, then soared by 66.22% to -$133224.0 in 2024, then slumped by 1493.05% to -$2.1 million in 2025, then surged by 91.74% to -$175256.0 in 2026.
  • Per Business Quant, the three latest BUDZ Net Income towards Common Stockholders figures stand at -$175256.0 (Q1 2026), -$2.1 million (Q4 2025), and -$73946.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Weed 3.10 Mn 3.10 Mn - -175,256.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -175,256.00
Dec 31, 2025 -2.12 Mn
Sep 30, 2025 -73,946.00
Jun 30, 2025 -107,616.00
Mar 31, 2025 -440,455.00
Dec 31, 2024 -133,224.00
Sep 30, 2024 -95,887.00
Jun 30, 2024 -110,953.00
Mar 31, 2024 -170,652.00
Dec 31, 2023 -394,368.00
Sep 30, 2023 734,248.00
Jun 30, 2023 -3.99 Mn
Mar 31, 2023 -197,014.00
Dec 31, 2022 -192,312.00
Sep 30, 2022 -2.99 Mn
Jun 30, 2022 -3.08 Mn
Mar 31, 2022 -3.28 Mn
Dec 31, 2021 -467,504.00
Sep 30, 2021 -182,101.00
Jun 30, 2021 -1.22 Mn